Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 28 (2), 165-173

Estimating Cumulative Point Prevalence of Rare Diseases: Analysis of the Orphanet Database

Affiliations

Estimating Cumulative Point Prevalence of Rare Diseases: Analysis of the Orphanet Database

Stéphanie Nguengang Wakap et al. Eur J Hum Genet.

Abstract

Rare diseases, an emerging global public health priority, require an evidence-based estimate of the global point prevalence to inform public policy. We used the publicly available epidemiological data in the Orphanet database to calculate such a prevalence estimate. Overall, Orphanet contains information on 6172 unique rare diseases; 71.9% of which are genetic and 69.9% which are exclusively pediatric onset. Global point prevalence was calculated using rare disease prevalence data for predefined geographic regions from the 'Orphanet Epidemiological file' (http://www.orphadata.org/cgi-bin/epidemio.html). Of the 5304 diseases defined by point prevalence, 84.5% of those analysed have a point prevalence of <1/1 000 000. However 77.3-80.7% of the population burden of rare diseases is attributable to the 4.2% (n = 149) diseases in the most common prevalence range (1-5 per 10 000). Consequently national definitions of 'Rare Diseases' (ranging from prevalence of 5 to 80 per 100 000) represent a variable number of rare disease patients despite sharing the majority of rare disease in their scope. Our analysis yields a conservative, evidence-based estimate for the population prevalence of rare diseases of 3.5-5.9%, which equates to 263-446 million persons affected globally at any point in time. This figure is derived from data from 67.6% of the prevalent rare diseases; using the European definition of 5 per 10 000; and excluding rare cancers, infectious diseases, and poisonings. Future registry research and the implementation of rare disease codification in healthcare systems will further refine the estimates.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Representation of epidemiological data in the Orphanet database
Fig. 2
Fig. 2
Selection process of point prevalence data from the Orphanet database’s epidemiological file for analysis
Fig. 3
Fig. 3
Distribution of inheritance patterns of genetic rare diseases. Genetic diseases were those in the ‘Orphanet classification of genetic diseases’, at the clinical entity ‘disorder’ level (excluding disorder groups and disorder subtypes)
Fig. 4
Fig. 4
Distribution of rare diseases and rare disease patients according to the point prevalence class. For each prevalence class both the number of rare diseases and the range of patients with rare diseases are shown. The inclusivity of each prevalence class in national definitions of ‘rare disease’ is shown below

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Valdez R, Ouyang L, Bolen J. Public health and rare diseases: oxymoron no more. Prev Chronic Dis. 2016;13:E05. - PMC - PubMed
    1. EURORDIS. Rare diseases: understanding this public health priority. 2005. http://www.eurordis.org/publication/rare-diseases-understanding-public-health-priority. Accessed 15 Jan 2019.
    1. Huyard C. How did uncommon disorders become ‘rare diseases’? History of a boundary object. Soc Health Illn. 2009;31:463–77. doi: 10.1111/j.1467-9566.2008.01143.x. - DOI - PubMed
    1. European Union. Regulation (EC) N°141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. 2000. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:EN:PDF. Accessed 15 Jan 2019.
    1. Van Weely S, Leufkens HGM. Priority Medicines for Europe and the World “A Public Health Approach to Innovation”: Background Paper 6.19 Rare Diseases. 2004. https://www.who.int/medicines/areas/priority_medicines/BP6_19Rare.pdf. Accessed 15 Jan 2019.
Feedback